Matrix Metalloproteinases in Cardioembolic Stroke: From Background to Complications

Area of Science:

• Neuroscience
• Biochemistry
• Cardiovascular Science

Background:

• Matrix metalloproteinases (MMPs) are crucial enzymes in brain physiology, blood-brain barrier integrity, and cerebral ischemia.
• MMP expression and activity are altered during stroke, influencing both acute damage and post-stroke recovery.
• Imbalances in MMPs and their inhibitors contribute to fibrosis, increasing atrial fibrillation (AF) risk, a major cause of cardioembolic strokes.

Purpose of the Study:

• To review the multifaceted role of MMPs in ischemic stroke, particularly cardioembolic stroke.
• To explore the connection between MMPs, cardiovascular risk factors (CHA2DS2-VASc score), and stroke complications.
• To discuss MMPs' genetic basis, regulation, clinical risk factors, and impact on patient outcomes.

Main Methods:

• Literature review focusing on MMPs in ischemic and cardioembolic stroke.
• Analysis of MMPs' involvement in physiological and pathological brain processes.
• Examination of MMPs' association with cardiovascular diseases and stroke complications.

Main Results:

• MMPs are critical in acute stroke phases, potentially worsening outcomes, and in post-stroke healing via tissue remodeling.
• MMP dysregulation is linked to hypertension, diabetes, heart failure, and vascular disease, factors contributing to stroke risk in AF patients.
• MMPs activated by reperfusion can exacerbate hemorrhagic complications, impacting overall stroke prognosis.

Conclusions:

• MMPs play a complex, dual role in ischemic stroke, influencing both pathology and recovery.
• Understanding MMPs' genetic and regulatory pathways is key to managing stroke risk and complications, especially in AF patients.
• Further research into MMPs' impact on clinical outcomes is warranted for improved therapeutic strategies.